Myeloid Therapeutics begins administering MT-303, a new RNA CAR targeting GPC3, in a Phase 1 trial for late-stage hepatocellular carcinoma (HCC).

Lotilaner ophthalmic, marketed under the brand name Xdemvy, has been approved by the FDA for the treatment of Demodex blepharitis.

SanBio Gains Approval for "AKUUGO® Suspension for Intracranial Use" (INN: Vandefitemcel) to Treat Persistent Motor Paralysis from Traumatic Brain Injuries.

Donislecel, branded as Lantidra, was approved by the FDA on June 28, 2023. It represents a significant development in the treatment of type 1 diabetes.

The combination therapy was well tolerated, and the safety profile of BNT111 with cemiplimab was consistent with previous trials of BNT111 with anti-PD-(L)1-based treatments.

Rozanolixizumab, marketed under the brand name Rystiggo, was approved by the FDA on June 26, 2023.

Tectonic Therapeutic has announced that the U.S. Food and Drug Administration has approved its Investigational New Drug application for TX45.

Ritlecitinib, marketed under the brand name Litfulo, received FDA approval on June 23, 2023, specifically for the treatment of severe alopecia areata.

FibroGen Releases Main Outcomes from Two Advanced Pamrevlumab Pancreatic Cancer Trials and Shares Corporate News.

Delandistrogene moxeparvovec, known by the brand name Elevidys, received FDA approval for the treatment of Duchenne muscular dystrophy in children on June 22, 2023.

Umoja Biopharma Receives FDA Approval for IND Application of UB-VV111, a CD19 Targeted CAR T for Blood Cancers.

Vyvgart Hytrulo received FDA approval on June 20, 2023. It is approved for the treatment of adults with generalized myasthenia gravis (gMG) who are anti-acetylcholine receptor (AChR) antibody positive.